Meningococcal Polysaccharide Vaccine

AIM Persistence Biopharmaceutical Co., Ltd. is a manufacturer and supplier of Meningococcal Polysaccharide Vaccine from China. Our product precisely protects against four prevalent serotypes of meningococcal bacteria: A, C, Y, and W135, providing more comprehensive protection than traditional single-type and dual-type meningococcal polysaccharide vaccines.

Who Is Recommended to Receive the Meningococcal Polysaccharide Vaccine?

Currently, vaccination is only recommended for children aged 2 years and older and adults in the following high-risk groups:

1. Individuals traveling to or residing in high-risk areas, such as the African meningitis belt (areas where serogroups A, C, Y, and W135 of Neisseria meningitidis are prevalent).

2. Individuals who may be exposed to Neisseria meningitidis serogroups A, C, Y, and W135 through airborne contact in laboratory or vaccine production work.

3. High-risk individuals in areas where national health authorities predict outbreaks of Neisseria meningitidis serogroups A, C, Y, and W135 infection based on epidemiological investigations.

Instructions for Use

1. Open the vaccine vial, add the specified amount of diluent for reconstitution, shake well, and use immediately.

2. Meningococcal Polysaccharide Vaccine is administered by subcutaneous injection, at the deltoid muscle attachment site on the outer aspect of the upper arm.

3. Dosage: Children over 2 years of age and adults receive one dose, 0.5 ml per person. Vaccination should be completed before the meningococcal meningitis epidemic season.

4. Booster Immunization: In epidemic areas, high-risk individuals, especially children under 4 years of age at the time of initial vaccination, should consider a booster immunization 2-3 years after the initial immunization if they remain at high risk.

Although the need for booster immunization in older children and adults has not yet been determined, if antibody levels decline rapidly 2-3 years after vaccination, a booster immunization should be considered 3-5 years after the initial immunization.

Currently, there is no research data on the duration of immunity and booster immunization for this product.

Product Experimental Data

A clinical trial involving 900 people showed that the antibody seroconversion rates of four serological tests A, C, W135, and Y of Meningococcal polysaccharide were all greater than 96% one month after vaccination, indicating good immunogenicity.

Xinercong ® series vaccine has a shelf life of up to 36 months. (High water content in freeze-dried formulations can affect the shelf life and stability.)

Why Choose Us?

AIM Persistence implements stricter internal control standards for bacterial endotoxin residue in our products, resulting in lower residue levels and improved safety; the 100KD imported membrane ultrafiltration process ensures high antigen purity.

The Meningococcal Polysaccharide Vaccine contains no preservatives, making it safer for preventive use. The entire manufacturing process is controlled in a B+A grade cleanroom environment, ensuring high cleanliness and product safety.

Post-vaccination safety observations show extremely low incidence of adverse reactions such as fever, local redness, swelling, and pain.

Professional and modern production workshops are the cornerstone of high-quality products!